These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22047047)

  • 1. Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.
    Casotti JA; Passos LN; Oliveira FJ; Cerutti C
    BMC Infect Dis; 2011 Nov; 11():306. PubMed ID: 22047047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.
    Thorsteinsson K; Ladelund S; Jensen-Fangel S; Johansen IS; Katzenstein TL; Pedersen G; Storgaard M; Obel N; Lebech AM
    BMC Infect Dis; 2012 Nov; 12():293. PubMed ID: 23140254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
    Silveira MP; Maurer P; Guttier MC; Moreira LB
    J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.
    Kim KH; Yi J; Lee SH
    Korean J Intern Med; 2015 Sep; 30(5):705-13. PubMed ID: 26354065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
    Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.
    Kulkarni H; Okulicz JF; Grandits G; Crum-Cianflone NF; Landrum ML; Hale B; Wortmann G; Tramont E; Polis M; Dolan M; Lifson AR; Agan BK; Ahuja SK; Marconi VC
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):387-95. PubMed ID: 21546844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
    Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
    Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
    Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.
    Gilson RJ; Man SL; Copas A; Rider A; Forsyth S; Hill T; Bansi L; Porter K; Gazzard B; Orkin C; Pillay D; Schwenk A; Johnson M; Easterbook P; Walsh J; Fisher M; Leen C; Anderson J; Sabin CA;
    HIV Med; 2010 Feb; 11(2):152-60. PubMed ID: 19732175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
    Mendes-Correa MC; Pinho JR; Gomes-Gouvea MS; da Silva AC; Guastini CF; Martins LG; Leite AG; Silva MH; Gianini RJ; Uip DE
    BMC Infect Dis; 2011 Sep; 11():247. PubMed ID: 21933423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.